• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $AIXC

    AIxCrypto Holdings Inc.

    Subscribe to $AIXC
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2015

    Exchange: NASDAQ

    Recent Analyst Ratings for AIxCrypto Holdings Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    AIxCrypto Holdings Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Wang Jiawei claimed ownership of 1,658 shares (SEC Form 3)

    3 - AIxCrypto Holdings, Inc. (0001460702) (Issuer)

    12/5/25 7:46:10 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. SEC Filings

    View All

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    5/28/26 5:23:37 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    5/14/26 4:31:14 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    5/11/26 8:00:14 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by AIxCrypto Holdings Inc.

    10-Q - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    5/11/26 4:30:41 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by AIxCrypto Holdings Inc.

    S-8 - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    4/17/26 4:24:47 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    4/16/26 4:05:34 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by AIxCrypto Holdings Inc.

    10-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    3/30/26 6:21:26 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    3/27/26 4:30:35 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    2/27/26 4:05:53 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    2/17/26 4:05:38 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIxCrypto Holdings Reports First Quarter 2026 Results; Highlights Q1 Execution Across Embodied AI, RWA Tokenization, and AI Agent Platforms

    Operational pipeline advances across all three 2026 revenue rails; aggregate Faraday Future investment position expanded to $12.0 million subsequent to quarter endLOS ANGELES, May 11, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC) (the "Company" or "AIxCrypto"), a Nasdaq-listed technology company building a three-layer architecture spanning the infrastructure, protocol, and application layers, today announced financial results for the first quarter ended March 31, 2026. Q1 2026 was the Company's first reporting period executing against the 2026 priorities laid out earlier this year following the September 2025 strategic transformation. The Company remains pre-revenue and is in t

    5/11/26 4:15:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Announces First Quarter 2026 Earnings Release Date and Conference Call Details

    LOS ANGELES, May 8, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a Nasdaq-listed technology company building a three-layer architecture spanning the infrastructure, protocol, and application layers, today announced that the Company is to hold an earnings call at 4:30 PM Pacific Time (7:30 PM Eastern Time) on Monday, May 11, 2026. AIxC invites stockholders to submit questions in advance of the upcoming earnings call. Stockholders may email their questions directly to: IR@aixcrypto.ai. We welcome your participation and appreciate your continued support.A live webcast of the conference call will be available in Events section of the Company's IR website

    5/8/26 8:00:00 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Agentir Progress, Chutes AI Collaboration Framework, and Bitcoin 2026 Engagement

    LOS ANGELES, May 5, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a Nasdaq-listed technology company building a three-layer architecture spanning the infrastructure, protocol, and application layers, today shared a weekly business update highlighting progress across its infrastructure support for the Agentir platform, Chutes AI collaboration framework, and external industry engagement at Bitcoin 2026. Agentir Development ProgressDuring the week, AIxC continued technical integration and infrastructure preparation for Agentir, an ecosystem initiative featuring an on-chain AI Agent competitive platform. The product is in the final stage of testing, optim

    5/5/26 4:11:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Announces Strategic Collaboration Framework with Chutes AI to Support AI Agent Infrastructure Scaling

    Exploring Decentralized Compute Infrastructure to Enhance Real-Time AI Agent Performance and Platform ScalabilityLOS ANGELES, April 30, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a Nasdaq-listed technology company building a three-layer architecture spanning the infrastructure, protocol, and application layers, today announced that it has entered into a non-binding collaboration framework with Chutes AI to explore infrastructure support and technical integration opportunities for AIxC's AI agent and application-layer ecosystem. The collaboration is intended to evaluate how decentralized compute infrastructure may support the scaling requirements of

    4/30/26 5:55:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto's Designated Investor and Faraday Future Complete Amendment to $12 Million Investment Agreement,Exploring RWA-Related Applications and Integration of Real-World Assets with Blockchain Infrastructure

    Key Points:An amendment to the securities purchase agreement dated January 30, 2026 (the "SPA") removed the true-up share mechanism and replaced it with a milestone-linked warrant capped at one million shares at $1.50 per shareThe Amended and Restated SPA increases the total investment amount to $12 millionThe warrant has a term expiring in April 2030 and is exercisable only upon delivery of 500 FX Super One vehiclesThe AIXC ecosystem is exploring the potential for a portion of the acquired FFAI shares to serve as underlying assets for future equity tokenization initiatives facilitated by ecosystem participants, subject to applicable regulatory and third-party approvalsLOS ANGELES, April 17,

    4/17/26 5:32:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    Faraday Future Amends $10 Million Equity Investment Agreement to $12 Million, Eliminating Anti-Dilution Provision to Strengthen Stockholder Protections

    Increase the Subscription Amount from $10 million to $12 million, $500,000 of which was used to purchase shares of Common Stock and $11.5 million of which was used to purchase shares of the Company's newly designated Series C preferred stock, which is convertible into the Company' Common Stock. AIXC and the designated third-party will use the US$500,000 of common stock to explore the real-world asset (RWA) business. Replace the true-up provision by issuance of a warrant. On the Closing Date, the Company issued to the Investor a warrant to purchase up to 1,000,000 shares of Common Stock at an exercise price of $1.50 per share with a term of 4 years, exercisable only after the delivery

    4/15/26 6:30:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: RWA Exploration, Ecosystem Development, and External Engagement

    LOS ANGELES, April 14, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a Nasdaq-listed technology company building a three-layer architecture spanning the infrastructure, protocol, and application layers, today shared a weekly business update highlighting progress across its RWA initiatives, ecosystem development, and external engagement. Advancing RWA Infrastructure ExplorationDuring the week, AIxC continued to advance its real-world asset (RWA) initiatives across multiple workstreams, with a focus on exploring infrastructure that enables the on-chain representation of traditional financial assets.The Company has initiated early-stage engagement with a

    4/14/26 1:28:00 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: AI Agent Development and Internal Testing Progress

    LOS ANGELES, April 6, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a technology company focused on infrastructure for the emerging Embodied AI (EAI) and on-chain asset ecosystem, today shared a weekly business update from Co-CEO Jerry Wang highlighting continued progress in the Company's AI Agent strategy, including ongoing development across key modules and the start of initial internal enterprise testing aimed at supporting workflow optimization and practical use case refinement. Advancing AI Agent-Related Development EffortsThis week, AIxC continued to advance its broader AI Agent strategy, with development work across key modules and supporting i

    4/6/26 11:42:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FF Announces Fourth Quarter and Full Year 2025 Financial Results: Stockholders' Equity Turns Positive; First Month of EAI Robotics Delivery Beats Target with Positive Product Gross Margin

    Balance sheet strengthens with return to positive stockholders' equity following ~$100 million debt optimization. EAI robotics exceeds target of shipping 20 units in its first delivery month and achieves positive product gross margins in Q1 2026, establishing a scalable growth and cash flow engine, targeting cumulative shipments of more than 1,000 units by the end of December 2026. The Company expects to generate software-related revenue beyond device sales within 2026. EAI EV Strategy advances into validation and pre-production with a disciplined, cash-aligned ramp. FF is the first U.S. company to deliver both humanoid and bionic robots that utilize a self-reinforcing "Device-Dat

    3/31/26 5:23:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Highlights Full Year 2025 Transformation and Next Phase of Growth

    LOS ANGELES, March 30, 2026 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a technology company focused on infrastructure for the emerging Embodied AI ("EAI") ecosystem, today highlighted key takeaways from its recently released full year 2025 results and provided an update on the Company's continued strategic development. Annual Report HighlightsFiscal year 2025 marked a foundational year for AIxC's strategic transformation. As outlined in the Company's annual results, AIxC completed its transition toward AI- and blockchain-enabled digital infrastructure, strengthened its capital position through financing activities, including the completion of a $41.0 million PIPE

    3/30/26 4:48:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. Leadership Updates

    Live Leadership Updates

    View All

    AIxC Appoints Andrew Grossman As Head of Legal Where He Will Direct the Company's Legal, Compliance, and Governance Strategy

    LOS ANGELES, Dec. 17, 2025 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC, ", AIxC", or ", the Company", )) today announced the appointment of Andrew Grossman as Head of Legal. In this role, Andrew will direct the Company's legal, compliance, and governance functions, managing key areas including SEC disclosures, fund and investment compliance, digital asset and Web3 protocol architecture, and major strategic and commercial agreements. Andrew brings extensive experience in securities regulation, digital asset ecosystem architecture, strategic corporate structuring, IP strategy, a

    12/17/25 1:01:00 AM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Holdings Inc. Financials

    Live finance-specific insights

    View All

    AIxCrypto Holdings Reports First Quarter 2026 Results; Highlights Q1 Execution Across Embodied AI, RWA Tokenization, and AI Agent Platforms

    Operational pipeline advances across all three 2026 revenue rails; aggregate Faraday Future investment position expanded to $12.0 million subsequent to quarter endLOS ANGELES, May 11, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC) (the "Company" or "AIxCrypto"), a Nasdaq-listed technology company building a three-layer architecture spanning the infrastructure, protocol, and application layers, today announced financial results for the first quarter ended March 31, 2026. Q1 2026 was the Company's first reporting period executing against the 2026 priorities laid out earlier this year following the September 2025 strategic transformation. The Company remains pre-revenue and is in t

    5/11/26 4:15:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Announces First Quarter 2026 Earnings Release Date and Conference Call Details

    LOS ANGELES, May 8, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a Nasdaq-listed technology company building a three-layer architecture spanning the infrastructure, protocol, and application layers, today announced that the Company is to hold an earnings call at 4:30 PM Pacific Time (7:30 PM Eastern Time) on Monday, May 11, 2026. AIxC invites stockholders to submit questions in advance of the upcoming earnings call. Stockholders may email their questions directly to: IR@aixcrypto.ai. We welcome your participation and appreciate your continued support.A live webcast of the conference call will be available in Events section of the Company's IR website

    5/8/26 8:00:00 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FF Announces Fourth Quarter and Full Year 2025 Financial Results: Stockholders' Equity Turns Positive; First Month of EAI Robotics Delivery Beats Target with Positive Product Gross Margin

    Balance sheet strengthens with return to positive stockholders' equity following ~$100 million debt optimization. EAI robotics exceeds target of shipping 20 units in its first delivery month and achieves positive product gross margins in Q1 2026, establishing a scalable growth and cash flow engine, targeting cumulative shipments of more than 1,000 units by the end of December 2026. The Company expects to generate software-related revenue beyond device sales within 2026. EAI EV Strategy advances into validation and pre-production with a disciplined, cash-aligned ramp. FF is the first U.S. company to deliver both humanoid and bionic robots that utilize a self-reinforcing "Device-Dat

    3/31/26 5:23:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Holdings Reports Full Year 2025 Financial Results; Highlights Transformational Pivot to AI and Blockchain Infrastructure

    LOS ANGELES, March 24, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC, or the ", Company", )), today reported financial results for the fiscal year ended December 31, 2025 — its inaugural annual earnings release following its transformation from a clinical-stage biopharmaceutical company into an AI and blockchain-enabled digital infrastructure company spanning Real World Asset (RWA) tokenization, AI agents and Embodied AI (EAI) blockchain ecosystems, connecting Web2 and Web3. Fiscal year 2025 was principally a period of strategic repositioning, capital formation, and platform development. The Company closed a $41.0 million private placement, rebranded from Qualigen Therapeutics,

    3/24/26 10:01:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details

    LOS ANGELES, March 20, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. ("AIxC" or the "Company"), a U.S.-Nasdaq listed company dedicated to building an ecosystem that integrates AI and blockchain while bridging Web2 and Web3, today announced that the Company is scheduled to report its fourth quarter financial results for 2025 after market close on Tuesday, March 24, 2026, and will hold an earnings call at 4:30 PM Pacific Time (7:30 PM Eastern Time) that same day. AIxC invites stockholders to submit questions in advance of the upcoming earnings call. Stockholders may email their questions directly to: IR@aixcrypto.ai. We welcome your participation and appreciate your continued support.Intereste

    3/20/26 4:15:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care